MAPK signaling pathway inhibitors (Columbia University/Columbia Technology Ventures)

N/A

Report date: 2025/01/26 19:03:21
NME

Base Information

Drug NameMAPK signaling pathway inhibitors (Columbia University/Columbia Technology Ventures)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMitogen-activated protein kinase inhibitors
TargetsMitogen-activated protein kinase
Therapy Area/IndicationsMuscular Dystrophy, Emery-Dreifuss
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesColumbia University
China Registration ClassN/A

Develop Information

Active CompaniesColumbia Technology VenturesColumbia University
Inactive CompaniesN/A
Active IndicationsMuscular Dystrophy, Emery-Dreifuss
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A